Cellectar Biosciences, Inc.

NasdaqCM:CLRB Stock Report

Market Cap: US$57.7m

Cellectar Biosciences Balance Sheet Health

Financial Health criteria checks 4/6

Cellectar Biosciences has a total shareholder equity of $16.5M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $37.3M and $20.7M respectively.

Key information

0%

Debt to equity ratio

US$0

Debt

Interest coverage ration/a
CashUS$34.26m
EquityUS$16.55m
Total liabilitiesUS$20.75m
Total assetsUS$37.29m

Recent financial health updates

We Think Cellectar Biosciences (NASDAQ:CLRB) Needs To Drive Business Growth Carefully

Aug 08
We Think Cellectar Biosciences (NASDAQ:CLRB) Needs To Drive Business Growth Carefully

Recent updates

We Think Cellectar Biosciences (NASDAQ:CLRB) Needs To Drive Business Growth Carefully

Aug 08
We Think Cellectar Biosciences (NASDAQ:CLRB) Needs To Drive Business Growth Carefully

Cellectar Biosciences: A Shoestring Opportunity You're About To Miss

Feb 12

Here's Why We're Watching Cellectar Biosciences' (NASDAQ:CLRB) Cash Burn Situation

Aug 23
Here's Why We're Watching Cellectar Biosciences' (NASDAQ:CLRB) Cash Burn Situation

Cellectar Biosciences GAAP EPS of -$1.22 misses by $0.19

Aug 05

Cellectar announces reverse stock split

Jul 21

We're Keeping An Eye On Cellectar Biosciences' (NASDAQ:CLRB) Cash Burn Rate

May 10
We're Keeping An Eye On Cellectar Biosciences' (NASDAQ:CLRB) Cash Burn Rate

Is Cellectar Biosciences (NASDAQ:CLRB) In A Good Position To Invest In Growth?

Jan 20
Is Cellectar Biosciences (NASDAQ:CLRB) In A Good Position To Invest In Growth?

Is Cellectar Biosciences (NASDAQ:CLRB) In A Good Position To Deliver On Growth Plans?

Oct 05
Is Cellectar Biosciences (NASDAQ:CLRB) In A Good Position To Deliver On Growth Plans?

Cellectar shares fall after mid-stage CLR 131 trial data fails to impress

Jun 04

We're Hopeful That Cellectar Biosciences (NASDAQ:CLRB) Will Use Its Cash Wisely

May 20
We're Hopeful That Cellectar Biosciences (NASDAQ:CLRB) Will Use Its Cash Wisely

Cellectar Biosciences EPS beats by $0.03

May 10

Cellectar gets notification of formal grant from Australian and Mexican patent authorities

Apr 27

Cellectar commences pivotal trial of CLR 131 in a rare form bone marrow cancer

Jan 12

Cellectar Bio readies stock offering

Dec 23

We're Keeping An Eye On Cellectar Biosciences' (NASDAQ:CLRB) Cash Burn Rate

Nov 30
We're Keeping An Eye On Cellectar Biosciences' (NASDAQ:CLRB) Cash Burn Rate

Cellectar Biosciences EPS beats by $0.05

Nov 09

Cellectar Bio's lead asset shows encouraging action in early-stage study of pediatric tumors

Nov 05

Financial Position Analysis

Short Term Liabilities: CLRB's short term assets ($35.9M) exceed its short term liabilities ($20.3M).

Long Term Liabilities: CLRB's short term assets ($35.9M) exceed its long term liabilities ($431.9K).


Debt to Equity History and Analysis

Debt Level: CLRB is debt free.

Reducing Debt: CLRB had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CLRB has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: CLRB has less than a year of cash runway if free cash flow continues to reduce at historical rates of 24.5% each year


Discover healthy companies